Pristinamycin

Jump to navigation Jump to search
Pristinamycin
Clinical data
ATC code
Identifiers
E number{{#property:P628}}
ECHA InfoCard{{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value).

WikiDoc Resources for Pristinamycin

Articles

Most recent articles on Pristinamycin

Most cited articles on Pristinamycin

Review articles on Pristinamycin

Articles on Pristinamycin in N Eng J Med, Lancet, BMJ

Media

Powerpoint slides on Pristinamycin

Images of Pristinamycin

Photos of Pristinamycin

Podcasts & MP3s on Pristinamycin

Videos on Pristinamycin

Evidence Based Medicine

Cochrane Collaboration on Pristinamycin

Bandolier on Pristinamycin

TRIP on Pristinamycin

Clinical Trials

Ongoing Trials on Pristinamycin at Clinical Trials.gov

Trial results on Pristinamycin

Clinical Trials on Pristinamycin at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on Pristinamycin

NICE Guidance on Pristinamycin

NHS PRODIGY Guidance

FDA on Pristinamycin

CDC on Pristinamycin

Books

Books on Pristinamycin

News

Pristinamycin in the news

Be alerted to news on Pristinamycin

News trends on Pristinamycin

Commentary

Blogs on Pristinamycin

Definitions

Definitions of Pristinamycin

Patient Resources / Community

Patient resources on Pristinamycin

Discussion groups on Pristinamycin

Patient Handouts on Pristinamycin

Directions to Hospitals Treating Pristinamycin

Risk calculators and risk factors for Pristinamycin

Healthcare Provider Resources

Symptoms of Pristinamycin

Causes & Risk Factors for Pristinamycin

Diagnostic studies for Pristinamycin

Treatment of Pristinamycin

Continuing Medical Education (CME)

CME Programs on Pristinamycin

International

Pristinamycin en Espanol

Pristinamycin en Francais

Business

Pristinamycin in the Marketplace

Patents on Pristinamycin

Experimental / Informatics

List of terms related to Pristinamycin

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

Pristinamycin (INN), also spelled pristinamycine, is an antibiotic used primarily in the treatment of staphylococcal infections, and to a lesser extent streptococcal infections. It is a streptogramin group antibiotic, similar to virginiamycin, derived from the bacterium Streptomyces pristina spiralis. It is marketed in Europe by Sanofi-Aventis under the trade name Pyostacine.

Pristinamycin is a mixture of two components that have a synergistic antibacterial action. Pristinamycin I is a macrolide, and results in pristinamycin having a similar spectrum of action to erythromycin. Pristinamycin II is a depsipeptide.[1]

Clinical use

Despite the macrolide component, it is effective against erythromycin-resistant staphylococci and strepcococci.[2][3] Importantly, it is active against methicillin-resistant Staphylococcus aureus (MRSA). Its usefulness for severe infections, however, may be limited by the lack of an intravenous formulation owing to its poor solubility.[4] Nevertheless it is sometimes used as an alternative to rifampicin+fusidic acid or linezolid for the treatment of MRSA.

The lack of an intravenous formulation led to the development of the pristinamycin-derivative quinupristin/dalfopristin, which may be administered intravenously for more severe MRSA infections.

See also

Footnotes

  1. Hamilton-Miller J (1991). "From foreign pharmacopoeias: 'new' antibiotics from old?". J Antimicrob Chemother. 27 (6): 702–5. PMID 1938680.
  2. Weber P (2001). "[Streptococcus pneumoniae: lack of emergence of pristinamycin resistance]". Pathol Biol (Paris). 49 (10): 840–5. PMID 11776696.
  3. Leclercq R, Soussy C, Weber P, Moniot-Ville N, Dib C (2003). "[In vitro activity of the pristinamycin against the isolated staphylococci in the french hospitals in 1999-2000]". Pathol Biol (Paris). 51 (7): 400–4. PMID 12948760.
  4. Edited by Sean C. Sweetman, ed. (November 30, 2004). Martindale: The complete drug reference (34th edition ed.). London: Pharmaceutical Press. ISBN 0-85369-550-4.

Template:SIB

th:ปริสตินามัยซิน

Template:WH Template:WS